Similar articles for PMID: 18695181

Year	Number of Results
1988	3
1989	6
1990	4
1991	3
1992	1
1993	2
1994	3
1996	2
1998	2
1999	1
2000	2
2001	2
2002	4
2003	6
2004	15
2005	4
2006	3
2007	8
2008	6
2009	8
2010	4
2011	3
2013	2
2015	2
2016	1
2019	1
2020	2
2024	0

1

Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response?

Zarychanski R, Houston DS. Zarychanski R, et al. CMAJ. 2008 Aug 12;179(4):333-7. doi: 10.1503/cmaj.071131. CMAJ. 2008. PMID: 18695181 Free PMC article. Review. No abstract available.

2

Erythropoietin pathophysiology and erythropoietin deficiency anemia.

Cazzola M. Cazzola M. Hematol J. 2004;5 Suppl 3:S100-3. doi: 10.1038/sj.thj.6200432. Hematol J. 2004. PMID: 15190288 Review. No abstract available.

3

Does TREAT give the boot to ESAs in the treatment of CKD anemia?

Singh AK. Singh AK. J Am Soc Nephrol. 2010 Jan;21(1):2-6. doi: 10.1681/ASN.2009111127. Epub 2009 Dec 24. J Am Soc Nephrol. 2010. PMID: 20035034 No abstract available.

4

Recombinant human Epo treatment: beneficial in chronic kidney disease, chronic heart failure, or both? Editorial to: "Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance by Pappas et al.".

Belonje AM, de Boer RA, Voors AA. Belonje AM, et al. Cardiovasc Drugs Ther. 2008 Feb;22(1):1-2. doi: 10.1007/s10557-008-6079-x. Cardiovasc Drugs Ther. 2008. PMID: 18219567 Free PMC article. No abstract available.

5

Erythropoietin to treat anaemia in patients with head and neck cancer.

Blumberg N, Heal JM. Blumberg N, et al. Lancet. 2004 Jan 3;363(9402):80-1; author reply 81-2. doi: 10.1016/S0140-6736(03)15186-0. Lancet. 2004. PMID: 14724011 No abstract available.

6

Guidelines for the use of recombinant human erythropoietin.

Barosi G, Cazzola M, De Vincentiis A, Grossi A, Tura S. Barosi G, et al. Haematologica. 1994 Nov-Dec;79(6):526-33. Haematologica. 1994. PMID: 7896210 No abstract available.

7

Breast cancer trial with erythropoietin terminated unexpectedly.

Leyland-Jones B; BEST Investigators and Study Group. Leyland-Jones B, et al. Lancet Oncol. 2003 Aug;4(8):459-60. doi: 10.1016/s1470-2045(03)01163-x. Lancet Oncol. 2003. PMID: 12901958 No abstract available.

8

Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.

Vaziri ND, Zhou XJ. Vaziri ND, et al. Nephrol Dial Transplant. 2009 Apr;24(4):1082-8. doi: 10.1093/ndt/gfn601. Epub 2008 Nov 5. Nephrol Dial Transplant. 2009. PMID: 18987263 No abstract available.

9

Erythropoietin: high profile, high scrutiny.

Crawford J. Crawford J. J Clin Oncol. 2007 Mar 20;25(9):1021-3. doi: 10.1200/JCO.2006.08.8153. Epub 2007 Feb 20. J Clin Oncol. 2007. PMID: 17312331 No abstract available.

10

Hypothesis versus association: the optimal hemoglobin target debate.

Strippoli GF, Craig JC. Strippoli GF, et al. Am J Kidney Dis. 2005 Nov;46(5):970-3. doi: 10.1053/j.ajkd.2005.09.009. Am J Kidney Dis. 2005. PMID: 16253741 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

96 results

Results by year